Back to top
more

Orthofix Medical (OFIX)

(Delayed Data from NSDQ)

$12.99 USD

12.99
258,973

-0.11 (-0.84%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $13.00 +0.01 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures

by Zacks Equity Research

According to Orthofix (OFIX), this data highlights the noninvasive and cost-effective nature of SpinalStim, enabling patients to continue their healing in the comfort of their homes.

Wall Street Analysts Believe Orthofix (OFIX) Could Rally 72.19%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 72.2% in Orthofix (OFIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Orthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View Cut

by Zacks Equity Research

Orthofix (OFIX) saw very strong growth across multiple business segments and product lines in Q3.

Does Orthofix (OFIX) Have the Potential to Rally 78.73% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 78.7% in Orthofix (OFIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Paragon 28, Inc. (FNA) Surges 12.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Hologic (HOLX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix (OFIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Orthofix (OFIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix (OFIX) Secures FDA 510k Clearance for OsteoCove Graft

by Zacks Equity Research

Orthofix (OFIX) announces the full commercial availability of the OsteoCove synthetic graft after gaining the FDA's nod.

Orthofix (OFIX) Soars 6.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Orthofix (OFIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Orthofix (OFIX) Unveils Gemini System, Advances in Trauma Wing

by Zacks Equity Research

According to Orthofix (OFIX), with the launch of the Galaxy Fixation Gemini system surgeons now have efficient solutions for lower extremity trauma scenarios where time is an important factor.

Should You Buy Orthofix (OFIX) After Golden Cross?

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market

by Zacks Equity Research

Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 102.99% and 1.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) Advances in ALIF Procedure With New Launch

by Zacks Equity Research

Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.

Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Orthofix (OFIX) delivered earnings and revenue surprises of 50% and 3.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Boston Scientific (BSX) outperforms the industry and the S&P 500 due to several new acquisitions and the long-term growth prospects of the WATCHMAN device.

Here's Why You Should Retain Amedisys (AMED) Stock for Now

by Zacks Equity Research

Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.

Why You Should Add Hologic (HOLX) to Your Portfolio Now

by Zacks Equity Research

Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Bruker Corporation (BRKR) outperforms the industry and the S&P 500 due to impressive quarterly results and segmental prospects.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips

by Zacks Equity Research

Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.

Orthofix (OFIX) Progresses With Limb-Lengthening Device

by Zacks Equity Research

Orthofix's (OFIX) Fitbone TAA intramedullary limb-lengthening system is implanted through a minimally invasive procedure.

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.

Amedisys (AMED) Faces Macro Challenges, Margin Pressure

by Zacks Equity Research

The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.

Teleflex (TFX) OEM Arm Grows, Supply Issue Persists

by Zacks Equity Research

From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.